• Education
    • Higher Education
    • Scholarships & Grants
    • Online Learning
    • School Reforms
    • Research & Innovation
  • Lifestyle
    • Travel
    • Food & Drink
    • Fashion & Beauty
    • Home & Living
    • Relationships & Family
  • Technology & Startups
    • Software & Apps
    • Startup Success Stories
    • Startups & Innovations
    • Tech Regulations
    • Venture Capital
    • Artificial Intelligence
    • Cybersecurity
    • Emerging Technologies
    • Gadgets & Devices
    • Industry Analysis
  • About us
  • Contact
  • Advertise with Us
  • Privacy & Policy
Today Headline
  • Home
  • World News
    • Us & Canada
    • Europe
    • Asia
    • Africa
    • Middle East
  • Politics
    • Elections
    • Political Parties
    • Government Policies
    • International Relations
    • Legislative News
  • Business & Finance
    • Market Trends
    • Stock Market
    • Entrepreneurship
    • Corporate News
    • Economic Policies
  • Science & Environment
    • Space Exploration
    • Climate Change
    • Wildlife & Conservation
    • Environmental Policies
    • Medical Research
  • Health
    • Public Health
    • Mental Health
    • Medical Breakthroughs
    • Fitness & Nutrition
    • Pandemic Updates
  • Sports
    • Football
    • Basketball
    • Tennis
    • Olympics
    • Motorsport
  • Entertainment
    • Movies
    • Music
    • TV & Streaming
    • Celebrity News
    • Awards & Festivals
  • Crime & Justice
    • Court Cases
    • Cybercrime
    • Policing
    • Criminal Investigations
    • Legal Reforms
No Result
View All Result
  • Home
  • World News
    • Us & Canada
    • Europe
    • Asia
    • Africa
    • Middle East
  • Politics
    • Elections
    • Political Parties
    • Government Policies
    • International Relations
    • Legislative News
  • Business & Finance
    • Market Trends
    • Stock Market
    • Entrepreneurship
    • Corporate News
    • Economic Policies
  • Science & Environment
    • Space Exploration
    • Climate Change
    • Wildlife & Conservation
    • Environmental Policies
    • Medical Research
  • Health
    • Public Health
    • Mental Health
    • Medical Breakthroughs
    • Fitness & Nutrition
    • Pandemic Updates
  • Sports
    • Football
    • Basketball
    • Tennis
    • Olympics
    • Motorsport
  • Entertainment
    • Movies
    • Music
    • TV & Streaming
    • Celebrity News
    • Awards & Festivals
  • Crime & Justice
    • Court Cases
    • Cybercrime
    • Policing
    • Criminal Investigations
    • Legal Reforms
No Result
View All Result
Today Headline
No Result
View All Result
Home Business & Finance Stock Market

FDA approves Revelation Biosciences’ drug trial for CKD By Investing.com todayheadline

December 2, 2024
in Stock Market
Reading Time: 3 mins read
A A
0
Cliffwater Enhanced Lending Fund director Garcia buys $500,000 in shares By Investing.com
3
SHARES
7
VIEWS
Share on FacebookShare on Twitter

SAN DIEGO – Revelation Biosciences Inc. (NASDAQ: REVB), a clinical-stage life sciences company with a market capitalization of $3.26 million, has received approval from the U.S. Food and Drug Administration (FDA) to proceed with a Phase 1b clinical trial of its drug candidate Gemini. The company’s stock, currently trading at $0.76, has experienced a significant decline of nearly 95% year-to-date, though according to InvestingPro analysis, the stock appears undervalued based on its Fair Value assessment. The study, set to begin in early 2025, aims to evaluate the safety and efficacy of Gemini as a preconditioning treatment for patients with chronic kidney disease (CKD).

The upcoming multi-site, placebo-controlled study will involve up to 40 subjects across 5 cohorts. The primary focus will be on the safety and tolerability of a single dose of Gemini in CKD patients. While the company maintains a healthy current ratio of 1.64 and holds more cash than debt, InvestingPro data indicates a rapid cash burn rate that investors should monitor. Additionally, secondary and exploratory endpoints will measure pharmacokinetics and the drug’s ability to modulate the innate immune response, which will be assessed using various biomarkers.

Revelation’s CEO, James Rolke, expressed pride in reaching this significant milestone and highlighted the company’s commitment to advancing patient care by leveraging trained immunity. This next phase of clinical research follows promising results from earlier Phase 1 trials, where Gemini met primary safety endpoints and showed significant pharmacodynamic activity.

Gemini, administered intravenously, is based on a proprietary formulation designed to reprogram the innate immune system, reducing damage related to inflammation. The drug has demonstrated potential in multiple preclinical studies for various indications, including reducing the severity and duration of acute kidney injury (AKI) and post-surgical infection, as well as halting or slowing the progression of CKD.

The success of the Phase 1b study is expected to pave the way for a Phase 2 trial, aiming to reduce AKI in patients undergoing coronary artery bypass graft and cardiac valve surgery. As the company moves forward with its clinical programs, it continues to explore Gemini’s potential across different treatment scenarios.

This announcement is based on a press release statement from Revelation Biosciences. The company cautions that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those anticipated. Investors are advised not to place undue reliance on these forward-looking statements, which reflect management’s current expectations as of the date of their publication. Despite current challenges, analyst price targets range from $5.50 to $20.00, suggesting potential upside. For deeper insights into REVB’s financial health and 11 additional ProTips, consider subscribing to InvestingPro.

In other recent news, Revelation Biosciences is facing potential delisting from the Nasdaq due to noncompliance with the minimum bid price and stockholders’ equity requirements. The San Diego-based pharmaceutical firm plans to appeal these notices and will request a hearing to maintain its listing status. In parallel, the company has entered into agreements to exercise Class D Common Stock Warrants for approximately 2.5 million shares, a strategy expected to generate around $3.8 million in gross proceeds.

Recently, Revelation Biosciences was ordered to pay a $7.3 million court judgment to LifeSci Capital LLC over a legal dispute, but the company has confirmed it has ample cash reserves to meet this judgment without impacting its ongoing development and clinical trial programs. In a positive development, the company reported promising results from a Phase 1 clinical trial for Gemini, its proprietary immune preconditioning therapy. Following this news, Roth Capital Partners (WA:) and MKM Partners maintained their Buy rating on Revelation Biosciences. These are the recent developments surrounding the company.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.


Previous Post

Depression May Trigger Severe Period Pain, Sleep Disturbances May Aggravate It: Study

Next Post

30-strong Nihon Hidankyo delegation to collect Nobel Peace Prize

Related Posts

What are next big copper projects? UBS tells when equipment makers could benefit todayheadline

June 7, 2025
9
Ohio food banks strain as Trump slashes federal aid programs

Ohio food banks strain as Trump slashes federal aid programs todayheadline

June 7, 2025
12
Next Post
30-strong Nihon Hidankyo delegation to collect Nobel Peace Prize

30-strong Nihon Hidankyo delegation to collect Nobel Peace Prize

  • Trending
  • Comments
  • Latest
Family calls for change after B.C. nurse dies by suicide after attacks on the job

Family calls for change after B.C. nurse dies by suicide after attacks on the job

April 2, 2025
Pioneering 3D printing project shares successes

Product reduces TPH levels to non-hazardous status

November 27, 2024

Hospital Mergers Fail to Deliver Better Care or Lower Costs, Study Finds todayheadline

December 31, 2024

Police ID man who died after Corso Italia fight

December 23, 2024
Harris tells supporters 'never give up' and urges peaceful transfer of power

Harris tells supporters ‘never give up’ and urges peaceful transfer of power

0
Des Moines Man Accused Of Shooting Ex-Girlfriend's Mother

Des Moines Man Accused Of Shooting Ex-Girlfriend’s Mother

0

Trump ‘looks forward’ to White House meeting with Biden

0
Catholic voters were critical to Donald Trump’s blowout victory: ‘Harris snubbed us’

Catholic voters were critical to Donald Trump’s blowout victory: ‘Harris snubbed us’

0
old hands

Resident-to-resident aggression is common in nursing homes. Here’s how we can improve residents’ safety

June 7, 2025
'What's the point?' That's dangerous, expert says

‘What’s the point?’ That’s dangerous, expert says

June 7, 2025

Trump signals case against Abrego Garcia will be ‘very easy’

June 7, 2025
Marcos, first lady light up Jones Bridge to mark 50 years of PH-China relations

Marcos, first lady light up Jones Bridge to mark 50 years of PH-China relations

June 7, 2025

Recent News

old hands

Resident-to-resident aggression is common in nursing homes. Here’s how we can improve residents’ safety

June 7, 2025
5
'What's the point?' That's dangerous, expert says

‘What’s the point?’ That’s dangerous, expert says

June 7, 2025
7

Trump signals case against Abrego Garcia will be ‘very easy’

June 7, 2025
6
Marcos, first lady light up Jones Bridge to mark 50 years of PH-China relations

Marcos, first lady light up Jones Bridge to mark 50 years of PH-China relations

June 7, 2025
5

TodayHeadline is a dynamic news website dedicated to delivering up-to-date and comprehensive news coverage from around the globe.

Follow Us

Browse by Category

  • Africa
  • Asia
  • Basketball
  • Business & Finance
  • Climate Change
  • Crime & Justice
  • Cybersecurity
  • Economic Policies
  • Elections
  • Entertainment
  • Entrepreneurship
  • Environmental Policies
  • Europe
  • Football
  • Gadgets & Devices
  • Health
  • Medical Research
  • Mental Health
  • Middle East
  • Motorsport
  • Olympics
  • Politics
  • Public Health
  • Relationships & Family
  • Science & Environment
  • Software & Apps
  • Space Exploration
  • Sports
  • Stock Market
  • Technology & Startups
  • Tennis
  • Travel
  • Uncategorized
  • Us & Canada
  • Wildlife & Conservation
  • World News

Recent News

old hands

Resident-to-resident aggression is common in nursing homes. Here’s how we can improve residents’ safety

June 7, 2025
'What's the point?' That's dangerous, expert says

‘What’s the point?’ That’s dangerous, expert says

June 7, 2025
  • Education
  • Lifestyle
  • Technology & Startups
  • About us
  • Contact
  • Advertise with Us
  • Privacy & Policy

© 2024 Todayheadline.co

Welcome Back!

OR

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Business & Finance
  • Corporate News
  • Economic Policies
  • Entrepreneurship
  • Market Trends
  • Crime & Justice
  • Court Cases
  • Criminal Investigations
  • Cybercrime
  • Legal Reforms
  • Policing
  • Education
  • Higher Education
  • Online Learning
  • Entertainment
  • Awards & Festivals
  • Celebrity News
  • Movies
  • Music
  • Health
  • Fitness & Nutrition
  • Medical Breakthroughs
  • Mental Health
  • Pandemic Updates
  • Lifestyle
  • Fashion & Beauty
  • Food & Drink
  • Home & Living
  • Politics
  • Elections
  • Government Policies
  • International Relations
  • Legislative News
  • Political Parties
  • Africa
  • Asia
  • Europe
  • Middle East
  • Artificial Intelligence
  • Cybersecurity
  • Emerging Technologies
  • Gadgets & Devices
  • Industry Analysis
  • Basketball
  • Football
  • Motorsport
  • Olympics
  • Climate Change
  • Environmental Policies
  • Medical Research
  • Science & Environment
  • Space Exploration
  • Wildlife & Conservation
  • Sports
  • Tennis
  • Technology & Startups
  • Software & Apps
  • Startup Success Stories
  • Startups & Innovations
  • Tech Regulations
  • Venture Capital
  • Uncategorized
  • World News
  • Us & Canada
  • Public Health
  • Relationships & Family
  • Travel
  • Research & Innovation
  • Scholarships & Grants
  • School Reforms
  • Stock Market
  • TV & Streaming
  • Advertise with Us
  • Privacy & Policy
  • About us
  • Contact

© 2024 Todayheadline.co